Vesalius Biocapital II S.A. SICAR

https://www.vesaliusbiocapital.com

Vesalius Biocapital (Vesalius), the specialist life sciences venture capital investor, has supported companies active in human health through venture capital funds since 2007. Since inception, Vesalius has raised over €260 million in three funds and contributed to the development of over 30 companies. The team consists of seasoned life science professionals with healthcare industry, corporate finance and strategy consulting experience, supporting companies through their growth cycle. The team is based in Europe and explores investment opportunities and valuation potential for the portfolio. Vesalius Biocapital III, launched in April 2017, announced a final close with EUR 120 million in commitments in 2019. The fund targets later-stage European life science companies in drug development, medtech, diagnostics and digital health. *

	Start	2011-01-01 established
	Group	Vesalius Biocapital (Group)
	Industry	venture capital
	Industry 2	BIOTECH

	Region	Luxembourg (cl=5)
	Country	Luxembourg
	Street	1B rue Thomas Edison
	City	1445 Strassen
	Tel	+352-26-845682
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	EUR
	Annual sales	78,000,000 (fund size (2017) 2017-05-18)

		* Document for »About Section«: Topas Therapeutics GmbH. (10/19/20). "Press Release: Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing". Hamburg.

		Record changed: 2024-02-12